Author of

• 12441

  +

  P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12469

    +

    P3.06-029 - Predictive role of serum tumor markers in NSCLC patients treated with erlotinib (ID 2433)

    09:30 - 09:30  |  Author(s): O. Topolcan
    • Abstract

    Background
    Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. Clinical trials proved its efficacy in patients with advanced-stage NSCLC. Although, activating EGFR gene mutations are currently the strongest predictor of erlotinib efficacy, the majority of NSCLC patiens harbor wild-type EGFR gene and moreover there is still a large proportion of patients in whom it is not feasible to acquire an adequate tissue for EGFR mutation analysis. We conducted this retrospective study aiming to prove the predictive role of tumor markers in patients with advanced-stage NSCLC treated with erlotinib.

    Methods
    144 patients with advanced-stage (IIIB, IV) NSCLC were treated with erlotinib (150 mg daily). Pretreatment serum levels of CEA, CYFRA 21-1, NSE and TK were assessed. Comparison of patients’survival (PFS and OS) according to the level of assessed tumor markers was performed using the log-rank test.

    Results
    Median PFS and OS for patients with normal CEA levels was 2.9 and 16.1 vs. 1.9 and 8.6 months in patients with high CEA levels (p = 0.046 and p = 0.116). Median PFS and OS for patients with normal CYFRA 21-1 levels was 3.4 and 23.8 vs. 1.9 and 6.1 months in patients with high CYFRA 21-1 levels (p < 0.01 and p < 0.01). Median PFS and OS for patients with normal NSE levels was 2.1 and 9.8 vs. 1.1 and 3.8 months in patients with high NSE levels (p = 0.051 and p = 0.022). Median PFS and OS for patients with normal TK levels was 2.1 and 23.7 vs. 2.0 and 8.5 months in patients with high TK levels (p = 0.110 and p = 0.037).

    Conclusion
    The study proved that high pretreatment levels of CEA, CYFRA 21-1 and NSE predict low efficacy of erlotinib treatment in patients with advanced-stage NSCLC. Assessment of these tumor markers is a good predictive tool for erlotinib treatment efficacy especially for those patients with unknown EGFR mutation status.